A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion.
William G. Wierda
Consultant or Advisory Role - Roche/Genentech
Research Funding - AbbVie; Roche/Genentech
John Francis Seymour
Consultant or Advisory Role - Roche/Genentech
Research Funding - AbbVie; Genentech
Andrew Warwick Roberts
Employment or Leadership Position - Walter and Eliza Hall Institute of Medical Research
Research Funding - AbbVie; Genentech
Soham Puvvada
No relevant relationships to disclose
Matthew Steven Davids
No relevant relationships to disclose
Shekman Wong
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Ming Zhu
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Elisa Cerri
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Rod Humerickhouse
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Stephan Stilgenbauer
Consultant or Advisory Role - AbbVie; Roche/Genentech
Research Funding - AbbVie; Roche